Full Press Release Details
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3.
IMMP
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Key Takeaway: Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3